The present invention relates to compounds of Formula (I), or a form thereof wherein ring A
1
, R
1
, R
2
, R
3
, R
3
′, L, W, and V are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.
AMES, D. E.;OPALKO, A., SYNTHESIS, 1983, N 3, 234-235
作者:AMES, D. E.、OPALKO, A.
DOI:——
日期:——
US9745328B2
申请人:——
公开号:US9745328B2
公开(公告)日:2017-08-29
[EN] FLAP MODULATORS<br/>[FR] MODULATEURS FLAP
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2014121055A2
公开(公告)日:2014-08-07
The present invention relates to compounds of Formula (I), or a form thereof, wherein ring A1, R1, R2, R3, R3', L, W, and V are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.
Synthesis and structure–activity relationship of N-(piperidin-4-yl)benzamide derivatives as activators of hypoxia-inducible factor 1 pathways
Guided by bioisosterism and pharmacokinetic parameters, we designed and synthesized a series of novel benzamide derivatives. Preliminary in vitro studies indicated that compounds 10b and 10j show significant inhibitory bioactivity in HepG2 cells (IC50 values of 0.12 and 0.13 μM, respectively). Compounds 10b and 10j induced the expression of HIF-1α protein and downstream target gene p21, and upregulated the expression of cleaved caspase-3 to promote tumor cells apoptosis.